about
Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumorsHigh-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cellsProtein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell linesmiRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumorsIdentifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression dataThe HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells - A data descriptionData integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8A in a breast cancer cell line.Integrative functional genomics analysis of sustained polyploidy phenotypes in breast cancer cells identifies an oncogenic profile for GINS2Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control studyIdentification of fusion genes in breast cancer by paired-end RNA-sequencing.Gene expression profiling of human dermal fibroblasts exposed to bleomycin sulphate does not differentiate between radiation sensitive and control patients.High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth.Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c.Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancerTumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses.Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitorsMetabolic clusters of breast cancer in relation to gene- and protein expression subtypesDrug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment responseIntegrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells.Genome signatures of colon carcinoma cell lines.Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.Advances in the genetics and epigenetics of gene regulation and human disease.Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors.DNA methylation at enhancers identifies distinct breast cancer lineages.Determinants of acquired activated protein C resistance and D-dimer in breast cancer.A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis.Correction: miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast TumorsTranscriptome teleonomy and scavenger lipidomics of albumin and alpha 1-acid glycoproteins: contextual genome-wide ontology enrichment as evidence for the epigenetic code?Breast cancer quantitative proteome and proteogenomic landscape
P50
Q28302352-B09E0E75-81EB-4FF3-A25C-C174A455CC94Q28534624-1491D723-D3AA-4C3E-9CB6-46E9DD16558AQ28651483-3B0FE015-8964-4CFF-9D0C-7E77EE50D9B3Q28742532-14559B61-FB2C-4973-94CC-E1797865F91BQ30587051-CCF97B2A-D934-4829-BA05-3DF28477B7C0Q31008419-25DA6A37-EF0E-4F15-8F0E-98E6C6CD7E77Q33443512-67824FE4-556F-41BE-A453-ABA4343B7A1AQ34311881-BB7FA685-7F47-4B7A-909D-75A9888075E2Q34611568-62EC7F5C-4676-49F4-BF89-8B2F620E2C6EQ34964405-804AEBC3-A2D9-4A89-895A-8CCD214B77A7Q35023605-2470C26D-7DCF-4FA4-96F9-18F411CC3848Q35024073-7750B1FC-7EBB-4323-8F5A-EBBC87B25739Q35104159-32328762-DC18-4743-80BB-6C9EE8055E17Q35410361-55C33772-311C-4F7F-A477-85C47D5A3928Q35579053-82D82C7C-A222-49EA-84AE-96F5F1101D93Q35589239-4B527F7B-8188-458F-8CD5-560EA85A93E8Q36916365-D538921A-6B7E-44F9-A56C-71E05DE5E479Q37040438-4E44B9B4-45A9-4C1A-AD07-0B91B6E828C0Q37722926-EADA935E-8462-4718-9A4B-C58EF21EEBECQ37728699-2035C9F4-4E1E-479A-9E63-0C7225CF56ABQ39223582-23FF3734-53D4-4158-B81E-63AFC6D390A9Q40486412-0C4A4250-B7FE-41DC-86EB-95BB32FA1E22Q41130424-D1C2954A-7D30-482C-98DB-D41CE34C09C6Q42990785-7EAAEE3D-D79A-40C0-84E3-8844E044E9A2Q43591112-700CFB48-9C1A-487B-A46F-CF9088304DFFQ43700782-03D580E2-AD20-4EAC-B09E-8CEEC500E47CQ51582637-81E7C2B9-4405-43AC-8342-38CD2A7165CFQ53651538-BE129927-9232-416E-A6D6-86A31B454141Q55025133-7C751D05-966B-4036-89CD-43F0F10C36F7Q57274743-83F7C855-B423-43CC-9BE5-23AB58F481B0Q57274793-2192D61B-64B3-44EE-AAA0-F905F3A7E931Q64067663-2DA51D14-C723-414F-8C79-A80B90746E42
P50
description
Noors onderzoekster
@nl
hulumtuese
@sq
norsk forsker
@nb
researcher
@en
ricercatrice
@it
name
Kristine Kleivi
@ast
Kristine Kleivi
@da
Kristine Kleivi
@de
Kristine Kleivi
@en
Kristine Kleivi
@es
Kristine Kleivi
@fr
Kristine Kleivi
@ga
Kristine Kleivi
@nb
Kristine Kleivi
@nl
Kristine Kleivi
@nn
type
label
Kristine Kleivi
@ast
Kristine Kleivi
@da
Kristine Kleivi
@de
Kristine Kleivi
@en
Kristine Kleivi
@es
Kristine Kleivi
@fr
Kristine Kleivi
@ga
Kristine Kleivi
@nb
Kristine Kleivi
@nl
Kristine Kleivi
@nn
altLabel
Kristine Kleivi Sahlberg
@en
prefLabel
Kristine Kleivi
@ast
Kristine Kleivi
@da
Kristine Kleivi
@de
Kristine Kleivi
@en
Kristine Kleivi
@es
Kristine Kleivi
@fr
Kristine Kleivi
@ga
Kristine Kleivi
@nb
Kristine Kleivi
@nl
Kristine Kleivi
@nn
P1015
P1015
P106
P21
P214
12145970073132250831
P2287
P27
P31
P569
2000-01-01T00:00:00Z
P6634
kristine-kleivi-sahlberg-06a3423